I misquoted them slightly
"The leverage ratio is expected to contract further this year but remains too steep for our liking" |
Not shooting the messenger here but the IC is not up with events in saying high leverage applies to HLN. At end-24 it had net debt of GBP7.9bn, 2.8x EBITDA, and down from GBP8.5bn at end-23. And during 2024 it spent GBP0.5bn on buybacks. HLN is throwing off cash and able to delever at a rapid enough clip if so minded. |
Tipped in IC fwiw, they think the China growth promise and brand strength outweigh the forex headwinds and high leverage. |
Seems good results did become good news after all. These results day negative reactions happen fairly regularly. |
Thank you Pilgrim |
4.6p per share, Ex-div 24 April payable 05 June. |
Could you tell me please how much the coming dividend is going be? |
In line. Hardly a crash considering the pre results run up. If you're looking for a crash try WPP. |
Good results doesn't mean Good news hence the Sp just crashed |
Positive price action ahead of results on 27th is encouraging. |
It still has 700 million and this sale has not affected the share price significantly. Perhaps because someone bought them! |
Further to the Launch Announcement, Pfizer has sold 700 million ordinary shares ("Ordinary Shares") in Haleon plc ("Haleon"), at a price of 357 pence ... |
Pfizer Offers to Sell 700 Million More Shares of Haleon |
Out for now. Luck to holders. |
Out for now. Luck to holders. |
Haleon (formerly GlaxoSmithKline Consumer Healthcare) announced its 'HealthNxt' initiative to make consumer healthcare more accessible to more people in India by leveraging digital innovation, content, and technology.
Launched in partnership with WPP, the initiative focuses on raising awareness and advancing healthcare education across India. |
Forward yield for 25 is only about 2% at 362p and a forecast 7.2p divi. |
#Anhar, a slow and steady growth share IMO, as the debt winds off dividends will increase, hopefully somewhere closer to the GSK 4% payout..
02.08.2023 - net debt at 30.06.2023 of GBP9,5BN with 3.4x net debt/adjusted EBITDA
29.02.2024 - net debt at 31.12.2023 of GBP8.5BN with 3.0x net debt/adjusted EBITDA
01.08.2024 - net debt at 30.06.2024 of GBP8.4BN with 2.9x net debt/adjusted EBITDA
31.10.2024 - target net debt/adjusted EBITDA of around 2.5x |
As an income investor I won't be adding at the current very low yield. Even a big rise in the divis of say 50% would still leave the yield too low for me to increase my holding with the share price around the present level. For most purchases, either top-ups or new holdings, I like to target a yield of at least 5% in current market conditions though I sometimes make exceptions to this for portfolio and diversification reasons.
I continue though to retain my holding from the GSK demerger as I think HLN has decent potential divi growth and my favoured approach is to to nothing. |
Yes, slippery slope continuing. Could really do with Pfizer dumping their final 15% |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
